A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours

Histopathology

Volumn 32, Issue 5, 1998, Pages 462-472

  Garcia Prats, M D ^a,b   Ballestin, C ^a   Sotelo, T ^a   Lopez Encuentra, A ^a   Mayordomo, J I ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b NONE   (Spain)

Author keywords

Carcinoma; Immunohistochemistry; Malignant mesothelioma

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CD15 ANTIGEN; CYTOKERATIN; EPITHELIAL MEMBRANE ANTIGEN; VIMENTIN;

ARTICLE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; MALIGNANT MESOTHELIOMA; PLEURA TUMOR; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MESOTHELIOMA; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

ZIZIPHUS MAURITIANA;

EID: 0031747578     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1998.00405.x     Document Type: Article

References (72)

1. Warhol MJ, Hickey WR, Corson JM. Malignant mesothelioma: ultrastructural distinction from adenocarcinonia. Am. J. Surg. Pathol. 1982; 6; 307-314.
2. Said JW, Nash G, Tepper G et al. Keratin proteins and carcinoembryonic antigen in lung carcinoma: An immunoperoxidase study of fifty-four cases, with ultrastructural correlation. Hum. Pathol. 1983: 14; 70-76.
3. Corson JM, Pinkus G. Mesothelioma: profile of cytokeratin proteins and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am. J. Pathol. 1982; 108; 80-87.
4. Holder J, Churg A. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am. J. Surg. Pathol. 1984; 8; 277-279.
5. Loosli H, Hurlimann J. Immunohistological study of malignant diffuse mesothelioma of the pleura. Histopathology 1984; 8; 793-803.
6. Battifora H, Kopinski M. Distiction of mesothelioma from adenocarcinoma: an immunohistochemical approach. Cancer 1985; 55; 1679-1685.
7. Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am. J. Surg. Pathol. 1985; 9: 360-365.
8. Gibbs AR, Harach R, Wagner JG et al. Comparison of tumor markers in malignant mesothelioma and pulmonary adenocarcinoma. Thorax 1985; 40; 91-95.
9. Sheihani K, Battifora H, Burke JJ. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. an antigen. Am. J. Pathol. 1986; 123; 212-219.
10. Szpak CA, Johnston WW, Roggli V et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung by a monoclonal antibody (B72.3). Am. J. Pathol. 1986; 122; 252-260.
11. Gnosh AK, Gatter KC, Dunnill MS et al. Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies. J. Clin. Pathol. 1987; 40; 19-25.
12. Lucas JG, Tultle SE. Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma. J. Surg. Oncol. 1987; 152: 309-316.
13. Otis DN, Carter D, Cole S et al. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma: a biinstitutional study of 47 cases. Am. J. Surg. Pathol. 1987: 11; 445-456.
14. Pfaltz M, Odermatt B, Christen B et al. Immunohistochemistry in the diagnosis of malignant mesothelioma. Virchows Arch. A Pathol. Anat. Histopathol. 1987; 411; 387-393.
15. Popper H, Winsberger G, Hoetler H et al. Immunohistochemical and histochemical markers of primary lung cancer, lung metastases, and pleural mesotheliomas. Cancer Detect. Prev. 1987; 10; 167-174.
16. a and anti-Tn antibodies. Hum. Pathol. 1989; 20; 53-57.
17. Ordoñez N. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am. J. Surg. Pathol. 1989; 13; 276-291.
18. Wirth PR, Legier J, Wright GL. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 1991: 67; 655-662.
19. Wick MR, Loy T, Mills SE et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: A histochemical. immunohistochemical and ultrastructural study of 103 cases. Hum. Pathol. 1990: 21: 759-766.
20. Marshall RJ, Herbert A, Brave SG et al. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma. mesothelioma and reactive endothelium. J. Clin. Pathol. 1984; 37; 1215-1221.
21. Tron V, Wright JL, Churg A. Carcinoembryonic antigen and milk fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung. Arch. Pathol. Lab. Med. 1987: 111: 291-293.
22. Benjamin CJ, Ritchie AC. Histological staining for the diagnosis of mesothelioma. Am. J. Med. Technol. 1982; 48: 905-908.
23. Fisher ER, Helstron R. The periodic acid Schiff reaction as an aid in the diagnosis of malignant mesothelioma. Cancer 1960; 13; 837-841.
24. Kwee WS, Veldhuizen RW, Golding RP et al. Histologic distinction between malignant mesothelioma. benign pleural lesion and carcinoma metastasis: Evaluation of the application of morphometry combined with histochemistry and immunostaining. Virchows Arch. A Anat. Pathol. Histopathol. 1982; 397; 287-299.
25. Jasani B, Edwards RE, Thomas ND et al. The use of vimentin antibodies in the diagnosis of malignant mesothelioma. Virchows Arch. (Pathol. Anat.) 1985; 406; 441-448.
26. Warnock ML, Stonof A, Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3 and Leu M1. Am. J. Pathol. 1988; 133; 30-38.
27. Nouwen EJ, Pollet DE, Eerdeckens MW et al. Immunohistochemical localization of placental alkaline phosphatase. carcinoembryonic antigen, and cancer antigen CA 125 in normal and neoplastic human lung. Cancer Res. 1986; 46; 866-876.
28. Bollinger DJ, Wick MR, Dehner LP et al. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma. A histochemical and immunohistochemical comparison. Am. J. Surg. Pathol. 1989; 13; 659-670.
29. Kondi-Paphitis A, Addis BJ. Secretory component in pulmonary adenocarcinoma and mesothelioma. Histopathology 1986; 10; 1279-1287.
30. Sheibani K, Shin SS, Kezirian J, Weiss LM. BER-EP4 as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am. J. Surg. Pathol 1991; 15; 779-784.
31. Gaffey MJ, Mills SE, Swanson PE et al. Immunoreactivity for Ber-EP4 in adenocarcinomas, adenomatoid tumors and malignant mesotheliomas. Am. J. Surg. Pathol. 1992; 16; 593-599.
32. Brown RW, Clark GM, Tandon AK, Allred DC. Multiple-marker immunohistochemical phenotypes distinguising malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum. Pathol. 1993; 24; 347-354.
33. Skov BG, Lauritzen AF, Hirsch FR, Skov T, Nielsen HW. Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproductivity of immunoreactive antibodies. Histopathology 1994: 25; 431-437.
34. Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: A stepwise logistic regression analysis. APMIS 1994; 102; 255-264.
35. Grove A, Paulsen SM, Gregersen M. The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastalic carcinoma. Path. Res. Pract. 1994; 190; 1044-1055.
36. Motoyama T, Watanabe T, Okazaki E, Tanaka M, Watanabe H, Imunohistochemical properties of malignant mesothelioma cells in histologic and cytologic specimens. Acta Cytol. 1995; 39; 164-170.
37. Adams VI, Unni KK. Diffuse malignant mesothelioma of the pleura: Diagnostic criteria based on an autopsy study. Am. J. Clin. Pathol. 1984; 82; 15-23.
38. Roggli VL, Kolbeck J, Sanfillippo F et al. Pathology of human mesothelioma: Etiologic and diagnostic considerations. Pathol. Ann. 1987; 22; 91-131.
39. Hsu SM, Raine L, Fanger H. The use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 1981; 29; 577-580.
40. Battifora H, Koplinski MI. The influence of protease digestion and duration of fixation on the immunostaining of keratins. A comparison of formalin and ethanol fixation. J. Histochem. Cytochem. 1986; 34; 1095-1100.
41. El-Naggar AK, Ro JY, Ayala AG et al. Localized fibrous tumor of the serosal cavities. Immunohistochemical. electron microscopic and flow cytometric DNA study. Am. J. Clin. Pathol. 1989: 92; 561-565.
42. Relea-Calatayud MF, Sotelo-Rodríguez T, Ballestín-Carcavilla C, Martínez-González MA, García-Prats MD. Tumor fibroso localizado pleural. Estudio óptico. ultraestructural e inmunohistoquímico de seis casos. Patologia (Madrid) 1993; 26; 289-295.
43. Rosai J, Lung and pleura. In Rosai J ed. Ackerman's Surgical Pathology. 7th edn. St. Louis: C.V. Mosby. 1989; 264-344.
44. Vogelzang NJ. Malignant mesothelioma: diagnostic and management strategies for 1992. Semin. Oncol. 1992: 19; 64-71.
45. Greco FA, Hainsworth JD. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site. Semin. Oncol. 1989; 16; 116-122.
46. Wagner JC, Munday DE, Harington JS. Histochemical demonstration of hyaluronic acid in human mesotheliomas. J. Pathol. Bacteriol. 1985: 16; 50-55.
47. Erlandson RA, Rosai J. A realistic approach to the use of electron microscopy and other ancillary techniques in surgical pathology. Am. J. Surg. Pathol. 1995; 19; 247-250.
48. Burns TR, Greenberg SD, Mace ML, Johnson EH. Ultrastructural diagnosis of epithelial malignant mesothelioma. Cancer 1985; 56; 2036-2040.
49. Suzuki Y, Churg J, Kannerstein M. Ultrastructure of human diffuse mesothelioma. Am. J. Pathol. 1976: 85; 241-262.
50. Warhol MJ, Corson JM. An ultrastructural comparison of mesotheliomas with adenocarcinomas of the lung and breast. Hum. Pathol. 1985: 16; 50-55.
51. Dardick I, Jabi M, McCaughey WTE, Deodhare S, van Nostrand AWB, Sigley JR. Diffuse epithelial mesothelioma: a review of the ultrastructural spectrum. Ultrastruct. Pathol. 1987; 11; 503-533.
52. Latza U, Niedobitek G, Schwarting R et al. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelia. J. Clin. Pathol. 1990; 43; 213-219.
53. O'Hara CJ, Corson JM, Pinkus GS et al. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am. J. Pathol. 1990; 136; 421-428.
54. Skov BG, Lauritzen AF, Hirsch FR, Nielsen HW. The histopathological diagnoses of malignant mesothelioma versus pulmonary adenocarcinoma. Reproducibility of the histopathological diagnoses. Histopathology 1994; 24; 553-557.
55. Weiss LM, Battifora H. The search for the optimal immunohistochemical panel for the diagnosis of malignant mesothelioma. Hum. Pathol. 1993; 24; 345-346.
56. Sheibani K. Immunopathology of malignant mesothelioma. Hum. Pathol. 1994; 25; 219-220.
57. Zeng L, Fleury-Feith J, Monnet I, Boutin C, Bignon J, Jaurand MC. Immunohistochemical characterization of cell lines from human malignant mesothelioma. Hum. Pathol. 1994: 25; 227-234.
58. Pass HI, Stevens EJ. Oie H et al. Characteristics of nine newly derived mesothelioma cell lines. Ann. Thorac. Surg. 1995: 59; 835-844.
59. Chenard-Neu MP, Bellocq JP, Batzenschlager A. Mesotheliomes malins de la plevre. Analyse de leurs aspects immunohistochimiques. Ann. Pathol. 1990; 10; 20-27.
60. Ernst CS, Brooks JJ. Immunoperoxidase localization of secretory component in reactive mesothelium and mesotheliomas. J. Histochem. Cytochem. 1981; 29; 1102-1104.
61. Cook HT. Decision analysis in immunohistochemistry. Lancet 1991: 338; 257.
62. Eills IA, Hitchcock A. Tumor marker reactivity in adenocarcinoma. J. Clin. Pathol. 1988: 41; 1064-1067.
63. Mayall FG, Goddard H, Gibbs AR. Intermediate filament expression in mesotheliomas: Leiomyoid mesotheliomas are not uncommon. Histopathology 1992; 21; 453-457.
64. Kung IT, Thallas V, Spencer EJ, Wilson SM. Expression of muscle actins in diffuse mesotheliomas. Hum. Pathol. 1995; 26; 565-570.
65. Hurlimann J. Desmin and neural cell marker expression in mesothelial cell lines and mesotheliomas. Hum. Pathol. 1994; 25; 753-757.
66. Schwarting R, Gredes J, Dürkop H, Falini B, Pileri S, Stein H. BER-H2: A new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 1989: 74; 1678-1689.
67. Mechtersheimer G, Möller P. Expression of Ki-1 antigen (CD30) in mesenchymal tumors. Cancer 1990; 66; 1732-1737.
68. Moll R, Lowe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker identified by monoclonal antibodies. Am. J. Pathol. 1992: 140; 427-447.
69. Hsu SM, Hsu PL, Zhao X et al. Establishment of human mesothelioma cell lines (MS-1, -2) and production of a monoclonal antibody (anti-MS) with diagnostic and therapeutic potential. Cancer Res. 1988: 48; 5228-5236.
70. Anderson TM, Holmes EC, Kosaka CJ et al. Monoclonal antibodies to human malignant mesothelioma. J. Clin. Immunol. 1987: 7; 247-261.
71. Chang K, Pai LH, Pass H et al. Monoclonal antibody MAb-K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am. J. Surg. Pathol 1990: 16; 259-268.
72. Allred DC, Puleo-Scheppke R, Brown RW et al. Monoclonal antibodies against malignant epithelial mesothelioma. Am. Rev. Respir. Dis. 1990: 141; A53.